Supplementary Data from Vandetanib, Designed to Inhibit VEGFR2 and EGFR Signaling, Had No Clinical Activity as Monotherapy for Recurrent Ovarian Cancer and No Detectable Modulation of VEGFR2

Authors:
  • CAChristina M. Annunziata
    Christina M. Annunziata
  • AWAmanda J. Walker
    Amanda J. Walker
  • LMLori Minasian
    Lori Minasian
  • MYMinshu Yu
    Minshu Yu
  • HKHerbert Kotz
    Herbert Kotz
  • BWBradford J. Wood
    Bradford J. Wood
  • KCKatherine Calvo
    Katherine Calvo
  • PCPeter Choyke
    Peter Choyke
  • DKDaniel Kimm
    Daniel Kimm
  • SSSeth M. Steinberg
    Seth M. Steinberg
  • EKElise C. Kohn
    Elise C. Kohn
Open Access
Publisher website
Google Scholar
Abstract
Supplementary Data from Vandetanib, Designed to Inhibit VEGFR2 and EGFR Signaling, Had No Clinical Activity as Monotherapy for Recurrent Ovarian Cancer and No Detectable Modulation of VEGFR2